Abstract
There is great heterogeneity in the way humans respond to medications, often requiring empirical strategies to define the appropriate drug therapy for each patient. Genetic polymorphisms in drug metabolizing enzymes, transporters, receptors, and other drug targets provide putative markers for predicting which patients will experience extreme toxicity and treatment failure. Both quantitative (allele frequency) and qualitative (specific allele) differences for polymorphic genes have been observed between different population groups. For example, the frequency of mutations in thiopurine methyltransferase is lower in Chinese than Caucasian populations. In addition, the predominant mutation responsible for deficient enzyme activity differs between the two populations (TPMT*3C versus TPMT*3A). Understanding the influence of ethnicity on pharmacogenomics will allow for comprehensive strategies for using the genome to optimize therapy for patients throughout the world.
Keywords: Pharmacogenetics, Pharmacogenomics, Ethnicity, TPMT, ABCB1, TYMS, VKORC1
Current Drug Targets
Title: Ethnic Differences in Pharmacogenetically Relevant Genes
Volume: 7 Issue: 12
Author(s): R. M. Engen, S. Marsh, D. J. Van Booven and H. L. McLeod
Affiliation:
Keywords: Pharmacogenetics, Pharmacogenomics, Ethnicity, TPMT, ABCB1, TYMS, VKORC1
Abstract: There is great heterogeneity in the way humans respond to medications, often requiring empirical strategies to define the appropriate drug therapy for each patient. Genetic polymorphisms in drug metabolizing enzymes, transporters, receptors, and other drug targets provide putative markers for predicting which patients will experience extreme toxicity and treatment failure. Both quantitative (allele frequency) and qualitative (specific allele) differences for polymorphic genes have been observed between different population groups. For example, the frequency of mutations in thiopurine methyltransferase is lower in Chinese than Caucasian populations. In addition, the predominant mutation responsible for deficient enzyme activity differs between the two populations (TPMT*3C versus TPMT*3A). Understanding the influence of ethnicity on pharmacogenomics will allow for comprehensive strategies for using the genome to optimize therapy for patients throughout the world.
Export Options
About this article
Cite this article as:
Engen M. R., Marsh S., Van Booven J. D. and McLeod L. H., Ethnic Differences in Pharmacogenetically Relevant Genes, Current Drug Targets 2006; 7 (12) . https://dx.doi.org/10.2174/138945006779025446
DOI https://dx.doi.org/10.2174/138945006779025446 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Advanced Glycation End Products and Insulin Resistance
Current Pharmaceutical Design Carotid Endarterectomy and Carotid Artery Stenting Lead to Improved Cognitive Performance in Patients with Severe Carotid Artery Stenosis
Current Neurovascular Research HMG-CoA Reductase Inhibitors (Statins) and their Drug Interactions Involving CYP Enzymes, P-glycoprotein and OATP Transporters-An Overview
Current Drug Metabolism Endogenous Cardioprotective Agents: Role in Pre and Postconditioning
Current Drug Targets Mitochondria-Targeted Antioxidants as a Therapeutic Strategy for Protecting Endothelium in Cardiovascular Diseases
Current Medicinal Chemistry Baseline Levels of Interleukine-6, Tumor-Necrosis Factor-Alpha and C-Reactive Protein in Treatment Naive Human Immunodeficiency Virus Infected Patients-A Study from a Tertiary-Care Hospital in Eastern India
Current Biomarkers (Discontinued) Evaluation of Salivary Lipid Peroxidation End Product Level in Dental Caries
Infectious Disorders - Drug Targets Clinical Aspects of Melatonin in the Acute Coronary Syndrome
Current Vascular Pharmacology The Role of Endothelin System in Cardiovascular Disease and the Potential Therapeutic Perspectives of its Inhibition
Current Topics in Medicinal Chemistry Association and Causal Relationship of Midlife Obesity and Related Metabolic Disorders with Old Age Cognition
Current Alzheimer Research From fungus to pharmaceuticals – the chemistry of statins
Mini-Reviews in Medicinal Chemistry Intimal Hyperplasia in Murine Models
Current Drug Targets The Bid to Lose Weight: Impact of Social Media on Weight Perceptions, Weight Control and Diabetes
Current Diabetes Reviews Aortic Arch Calcification and Mortality in Chronic Hemodialysis Patients
Reviews on Recent Clinical Trials Selenium Containing Compounds from Poison to Drug Candidates: A Review on the GPx-like Activity
Current Chemical Biology Treatment Strategies of Obsessive-Compulsive Disorder and Panic Disorder/Agoraphobia
Current Topics in Medicinal Chemistry Essential Fatty Acids - A Review
Current Pharmaceutical Biotechnology Mild Cognitive Impairment: At the Crossroad of Neurodegeneration and Vascular Dysfunction
Current Alzheimer Research Adeno-Associated Virus (AAV) Mediated Dystrophin Gene Transfer Studies and Exon Skipping Strategies for Duchenne Muscular Dystrophy (DMD)
Current Gene Therapy Exercise-Induced Modulation of Endothelial Nitric Oxide Production
Current Pharmaceutical Biotechnology